Vilya
Developing a novel class of drugs that precisely target the biology of disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
* | $21.0m Valuation: $250m | Series A | |
| Total Funding | 000k | ||
Related Content
Vilya is a computational biotechnology company developing a new class of medicines.
The company's platform is based on research from the Institute of Protein Design and utilizes advanced computational methods for drug design. This technology enables the creation of novel medicines that can precisely target the biological basis of diseases.
Vilya has secured significant investment, recently expanding its Series A financing to $71 million. This capital is intended to advance the development of its computational platform and accelerate its pipeline of therapeutic candidates. The business model focuses on creating a new class of medicines to address a range of diseases, potentially through internal development or partnerships within the pharmaceutical industry.
Keywords: computational biotechnology, drug design, drug discovery, protein design, disease targeting, novel medicines, biopharmaceuticals, therapeutics, molecular design, Series A